Ground Breaking on Research Facility

Aragen Bioscience, Inc., a leading CRO specialising in the study and early development of biologic and diagnostic products, has initiated construction on a new research facility dedicated to the testing and characterisation of novel therapeutics and vaccines. The 15,000 sq.ft addition to Aragen’s existing laboratories will double capacity for diverse efficacy studies for products to help improve diagnosis, treatment and prevention of disease including fibrotic and infectious disease, oncology and other immunologically related indications.

This project demonstrates Aragen’s commitment to future growth and meeting the needs of our clients for value-added services. The new facility not only expands general capacity, but is constructed for high technical performance and tight environmental control including provision of BSL-2 studies. We look forward to seeing the building progress and its opening later this year,” commented Dr. Malavika Ghosh, Aragen’s Vice President of Preclinical Services.

The facility, which is designed for AAALAC accreditation and GLP compliance, is scheduled to be functional in the second quarter of 2016.